From Genetic Engineering to Preclinical Safety: A Study on Recombinant Human Interferons

Area of Science:

• Biopharmaceutical Development
• Immunology
• Drug Safety

Background:

• Preclinical research on native recombinant human interferons (rhIFNα-2b and rhIFN-γ) is limited, focusing instead on modified variants.
• Understanding the properties of native interferons is crucial for accurate preclinical assessment.

Purpose of the Study:

• To comprehensively evaluate the structural stability and intrinsic toxicity of purified native rhIFNα-2b and rhIFN-γ.
• To establish a reproducible preclinical model for interferon evaluation.
• To support the safe transition of interferons to clinical trials.

Main Methods:

• Structural stability assessments under controlled conditions.
• Accelerated stability assays at various temperatures.
• Acute and sub-chronic toxicity studies in multiple animal models (rodent, non-rodent, higher organisms).
• Pyrogen testing.

Main Results:

• Both rhIFNα-2b and rhIFN-γ retained bioactivity (antiviral, antiproliferative, immunomodulatory).
• Proteins showed remarkable stability, with no loss of potency after 18 days in accelerated assays.
• No toxicity observed in animal models at doses 100-300 times higher than therapeutic levels.
• Assays confirmed the absence of pyrogens, indicating a favorable safety profile.

Conclusions:

• Purified native interferons exhibit significant stability and a favorable safety profile.
• The findings support the potential for liquid formulations and alternative administration routes, such as intranasal.
• Early characterization of API safety is vital for successful clinical translation.